Macomics Announces Neurodegeneration and Neuroinflammation Applications of ENIGMAC Drug Discovery Platform
Edinburgh and Cambridge, UK, 8 October 2025 - Macomics Ltd, a leader in macrophage drug discovery, announces that it has validated its ENIGMAC™ platform in neurodegeneration and neuroinflammation applications.